EGFR-targeted delivery of DOX-loaded Fe(3)O(4)@ polydopamine multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy

Multifunctional nanocomposites that have multiple therapeutic functions together with real-time imaging capabilities have attracted intensive concerns in the diagnosis and treatment of cancer. This study developed epidermal growth factor receptor (EGFR) antibody-directed polydopamine-coated Fe(3)O(4) nanoparticles (Fe(3)O(4)@PDA NPs) for magnetic resonance imaging and antitumor chemo-photothermal therapy. The synthesized Fe(3)O(4)@PDA-PEG-EGFR-DOX NPs revealed high storage capacity for doxorubicin (DOX) and high photothermal conversion efficiency. The cell viability assay of Fe(3)O(4)@PDA-PEG-EGFR NPs indicated that Fe(3)O(4)@ PDA-PEG-EGFR NPs had no cell cytotoxicity. However, Fe(3)O(4)@PDA-PEG-EGFR-DOX NPs could significantly decrease cell viability (~5% of remaining cell viability) because of both photothermal ablation and near-infrared light-triggered DOX release. Meanwhile, the EGFR-targeted Fe(3)O(4)@PDA-PEG-EGFR-DOX NPs significantly inhibited the growth of tumors, showing a prominent in vivo synergistic antitumor effect. This study demonstrated the potential of using Fe(3)O(4)@PDA NPs for combined cancer chemo-photothermal therapy with increased efficacy.